Our results highlight that a corresponding circulating PIK3CA mutation was identified in 55% of non-metastatic IBC patients with a baseline somatic PIK3CA mutation in tumour tissue and with detectable cfDNA, while no circulating mutation was found among patients with no PIK3CA mutations. Here, PIK3CA is linked to inflammatory breast carcinoma.